GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lotus Ventures Inc (XCNQ:J) » Definitions » Debt-to-Asset

Lotus Ventures (XCNQ:J) Debt-to-Asset : 0.18 (As of Aug. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Lotus Ventures Debt-to-Asset?

Lotus Ventures's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2023 was C$2.43 Mil. Lotus Ventures's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Aug. 2023 was C$0.00 Mil. Lotus Ventures's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Aug. 2023 was C$13.90 Mil. Lotus Ventures's debt to asset for the quarter that ended in Aug. 2023 was 0.18.


Lotus Ventures Debt-to-Asset Historical Data

The historical data trend for Lotus Ventures's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lotus Ventures Debt-to-Asset Chart

Lotus Ventures Annual Data
Trend Aug13 Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.02 0.04 0.02 0.08

Lotus Ventures Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.08 0.14 0.17 0.17 0.18

Competitive Comparison of Lotus Ventures's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Lotus Ventures's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lotus Ventures's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lotus Ventures's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Lotus Ventures's Debt-to-Asset falls into.



Lotus Ventures Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Lotus Ventures's Debt-to-Asset for the fiscal year that ended in Aug. 2022 is calculated as

Lotus Ventures's Debt-to-Asset for the quarter that ended in Aug. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lotus Ventures  (XCNQ:J) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Lotus Ventures Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Lotus Ventures's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Lotus Ventures (XCNQ:J) Business Description

Traded in Other Exchanges
Address
1030 West Georgia Street, Suite 1010, Vancouver, BC, CAN, V6E 2Y3
Lotus Ventures Inc is a licensed cannabis producer that serves customers in Canada. The company created a purpose-built facility with proprietary standard operating procedures to reliably produce rare and high-quality strains of cannabis for consumers looking for a consistent experience.
Executives
Gary Kenneth Mathiesen Senior Officer